keyword
MENU ▼
Read by QxMD icon Read
search

Autologous stem cell transplant

keyword
https://www.readbyqxmd.com/read/29025292/-brentuximab-vedotin-treatment-in-patients-with-relapsed-or-refractory-hodgkin-lymphoma-a-hungarian-retrospective-study
#1
Zsuzsa Molnár, László Imre Pinczés, Klára Piukovics, Ildikó Istenes, Krisztina Wolf, Zoltán Csukly, Árpád Szomor, Árpád Illés, Zsófia Miltényi
INTRODUCTION: The treatment of relapsed or refractory Hodgkin lymphoma is still a major therapeutic challenge. The use of brentuximab vedotin, an anti-CD30 antibody-drug conjugate, represents a promising approach for these patients, however clinical outcomes have not yet been evaluated in Hungary. AIM: Our aim was to assess the efficacy, safety and outcome of brentuximab vedotin treatment in Hungarian Hodgkin lymphoma patients. METHOD: In this retrospective case note review we enrolled patients at 6 clinical sites countrywide who were diagnosed with Hodgkin lymphoma and received brentuximab vedotin between 1 January 2013 and 31 December 2016...
October 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/29025289/-the-role-of-autologous-hemopoietic-stem-cell-transplantation-in-t-cell-lymphoma-hungarian-data
#2
Árpád Szomor, Renáta Csalódi, Szabolcs Kosztolányi, Ágnes Nagy, Judit Pammer, Orsolya Tóth, Hajna Losonczy, Hussain Alizadeh, Zsófia Miltényi, Péter Reményi, Klára Piukovics
T-cell lymphoma is a poor prognostic hematological malignancy. The generally used - not sufficiently effective - induction chemotherapy should be improved with consolidative autologous hemopoetic stem cell transplantation. The authors describe the role, place and effectiveness of transplantation in this disorder. One hundred thirty three autologous stem cell transplantations were performed in the last 22 years in Hungary. Detailed results are available from the last 6 years. In this period 43 transplantations were carried out in 4 Hungarian centers...
October 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/29025287/-incidence-and-treatment-of-extranodal-natural-killer-t-cell-lymphoma-nasal-type-hungarian-experiences
#3
Annamária Bakos, Árpád Szomor, Tamás Schneider, Zsófia Miltényi, Imelda Marton, Zita Borbényi, Judit Pammer, László Krenács, Enikő Bagdi, Klára Piukovics
INTRODUCTION: Extranodal natural killer/T (NK/T) cell lymphoma, nasal type (ENKTL) represents a rare subtype of T-cell lymphomas with aggressive clinical behavior according to WHO 2016 classification. AIM: ENKTL has distinctive geographic distribution with higher incidence in Asia and Latin America (10% of all non-Hodgkin lymphoma cases), than in Europe and North America (<1%). ENKTL tipically origins from nasopharynx and upper aerodigestive tract. Anthracycline-based chemotherapy regimens are largely ineffective in the treatment of ENKTL...
October 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/29025229/mechanical-supplementation-with-the-stromal-vascular-fraction-yields-improved-volume-retention-in-facial-lipotransfer-a-1-year-comparative-study
#4
Natale Ferreira Gontijo-de-Amorim, Luiz Charles-de-Sá, Gino Rigotti
Background: Unpredictable volume maintenance in the long term is a major limitation of autologous fat grafting. Objectives: The authors compared results of autologous lipotransfer to the face with or without enrichment of fat with the stromal vascular fraction (SVF). Methods: Thirty patients with asymmetric depletion of facial volume were included in a prospective study. Patients were randomly assigned to undergo a single session of autologous fat transfer with washed adipose tissue (control group) or with washed adipose tissue combined with the pellet of centrifuged lipoaspirate, which contained the SVF (enriched group)...
October 1, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/29020286/incidence-risk-factors-and-outcome-of-pre-engraftment-gram-negative-bacteremia-after-allogeneic-and-autologous-hematopoietic-stem-cell-transplantation-an-italian-prospective-multicenter-survey
#5
Corrado Girmenia, Alice Bertaina, Alfonso Piciocchi, Alessandra Carotti, Alessandra Algarotti, Alessandro Busca, Chiara Cattaneo, Anna Maria Raiola, Stefano Guidi, Anna Paola Iori, Anna Candoni, Giuseppe Irrera, Giuseppe Milone, Giampaolo Marcacci, Rosanna Scimè, Maurizio Musso, Laura Cudillo, Simona Sica, Luca Castagna, Paolo Corradini, Francesco Marchesi, Domenico Pastore, Emilio Paolo Alessandrino, Claudio Annaloro, Fabio Ciceri, Stella Santarone, Luca Nassi, Claudio Farina, Claudio Viscoli, Gian Maria Rossolini, Francesca Bonifazi, Alessandro Rambaldi, Gruppo Italiano
Background: Gram-negative bacteremia (GNB) is a major cause of morbidity and mortality in Hematopoietic Stem Cell Transplant (HSCT) and updated epidemiological investigation is advisable. Methods: We prospectively evaluated the epidemiology of pre-engraftment GNB in 1,118 allogeneic HSCT (allo-HSCT) and 1,625 autologous HSCT (auto-HSCT) among 54 transplant centers during 2014 (SIGNB-GITMO-AMCLI study). Using logistic regression methods we identified risk factors for GNB and evaluated the impact of GNB on the 4-month overall-survival after transplant...
August 3, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28993772/rescuing-self-transient-isolation-and-autologous-transplantation-of-bone-marrow-mitigates-radiation-induced-hematopoietic-syndrome-and-mortality-in-mice
#6
Subhajit Ghosh, Namita Indracanti, Jayadev Joshi, Prem Kumar Indraganti
The inflamed bone marrow niche shortly after total body irradiation (TBI) is known to contribute to loss of hematopoietic stem cells in terms of their number and function. In this study, autologous bone marrow transfer (AL-BMT) was evaluated as a strategy for mitigating hematopoietic form of the acute radiation syndrome by timing the collection phase (2 h after irradiation) and reinfusion (24 h after irradiation) using mice as a model system. Collection of bone marrow (BM) cells (0.5 × 10(6) total marrow cells) 2 h after lethal TBI rescued different subclasses of hematopoietic stem and progenitor cells (HSPCs) from the detrimental inflammatory and damaging milieu in vivo...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28991244/early-consolidation-with-high-dose-therapy-and-autologous-stem-cell-transplantation-is-a-feasible-and-effective-treatment-option-in-hiv-associated-non-hodgkin-lymphoma-at-high-risk
#7
A Re, G Gini, M Rupolo, A Levis, A Bandera, A M Liberati, P Tozzi, C Cattaneo, S Casari, C Skert, C Bocci, M Spina, B Allione, L Verga, M Michieli, C Almici, P F Leali, U Tirelli, G Rossi
No abstract text is available yet for this article.
October 9, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28991129/a-heterozygous-cfhr3-cfhr1-gene-deletion-in-a-pediatric-patient-with-transplant-associated-thrombotic-microangiopathy-who-was-treated-with-eculizumab
#8
Akifumi Nozawa, Michio Ozeki, Tomohiro Hori, Norio Kawamoto, Masahiro Hirayama, Eiichi Azuma, Toshiyuki Fukao
Complement system dysregulation, such as complement Factor H (CFH) autoantibodies and deletions in CFH-related (CFHR) genes 3 and 1, might cause transplant-associated thrombotic microangiopathy (TA-TMA). The use of eculizumab, a terminal complement inhibitor, could be a targeted therapy for TA-TMA. We report a 1-year-old girl who developed TA-TMA, just after autologous peripheral blood stem cell transplantation in neuroblastoma therapy. Eculizumab improved TA-TMA. Investigation for the complement alternative pathway showed a heterozygous CFHR3-CFHR1 gene deletion, which is involved in complement activation...
October 4, 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/28990128/a-single-center-retrospective-analysis-to-compare-the-efficacy-and-safety-of-filgrastim-sndz-to-filgrastim-for-prophylaxis-of-chemotherapy-induced-neutropenia-and-for-neutrophil-recovery-following-autologous-stem-cell-transplantation
#9
Julia Zecchini, Kendra Yum, Amir Steinberg, Cardinale Smith, Sara Kim
Filgrastim-sndz (Zarxio®) was approved by the FDA in March 2015 as a biosimilar product of its reference product, filgrastim (Neupogen®) for all five indications. The NCCN Clinical Practice Guidelines has incorporated filgrastim-sndz into its recommendations as a category 1 recommendation for use in settings of febrile neutropenia, myelosuppressive chemotherapy administration, and post-hematopoietic stem cell transplant (HSCT). As a cost-saving initiative, our institution switched from filgrastim to filgrastim-sndz for all indications starting in March 2016...
October 8, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28988692/the-survey-on-cellular-and-tissue-engineered-therapies-in-europe-and-neighboring-eurasian-countries-in-2014-and-2015
#10
Hilary Ireland, Max H P Gay, Helen Baldomero, Barbara De Angelis, Hossein Baharvand, Mark W Lowdell, Jakob Passweg, Ivan Martin
BACKGROUND AIMS: With the support of five established scientific organizations, this report, the seventh of its kind, describes activity in Europe for the years 2014 and 2015 in the area of cellular and tissue-engineered therapies, excluding hematopoietic stem cell (HSC) treatments for the reconstitution of hematopoiesis. METHODS: In 2015 [respectively 2014], 205 [276] teams from 32 countries responded to the cellular and tissue-engineered therapy survey; 178 [126] teams reported treating 3686 [2665] patients...
October 4, 2017: Cytotherapy
https://www.readbyqxmd.com/read/28987247/impact-of-autologous-stem-cell-transplantation-on-blood-pressure-and-renal-function-in-multiple-myeloma-patients
#11
Leah Balsam, Chadi Saad, Camelia Arsene, Joshua Fogel
BACKGROUND: Autologous stem cell transplantation (ASCT) reverses kidney failure in one-third of multiple myeloma (MM) patients, which may lead to blood pressure (BP) improvement. We evaluate the long term impact of ASCT on BP and renal function in MM patients. METHODS: We studied 192 MM patients that underwent ASCT. We compared BP readings and glomerular filtration rate (GFR) at 4 weeks before ASCT, on day of ASCT and post-ASCT at 30, 100 and 180 days. RESULTS: Mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) on day of ASCT and at both 30 and 100 days post-ASCT was significantly lower as compared to pre-ASCT SBP and DBP...
2017: Journal of the National Medical Association
https://www.readbyqxmd.com/read/28985769/low-toxicity-and-favorable-clinical-and-quality-of-life-impact-after-non-myeloablative-autologous-hematopoietic-stem-cell-transplant-in-crohn-s-disease
#12
Milton Artur Ruiz, Roberto Luiz Kaiser, Luiz Gustavo de Quadros, Lilian Piron-Ruiz, Tatiana Peña-Arciniegas, Mikaell Alexandre Gouvea Faria, Rubens Camargo Siqueira, Flavio Fontes Pirozzi, Fernanda Soubhia Liedtke Kaiser, Richard K Burt
OBJECTIVE: The incidence of adverse events in myeloablative transplant protocols is high in refractory Crohn's disease; this study used low doses of cyclophosphamide. Fourteen patients were submitted to non-myeloablative autologous hematopoietic stem cell transplantation. RESULTS: The average number of days of anemia (hemoglobin < 10 g/dL) was 5.4 ± 4.2 and 14 ± 2.4 in the mobilization and conditioning phases, respectively. The mean number of days of neutropenia (neutrophils < 0...
October 6, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/28984258/hepatic-sinusoidal-obstruction-syndrome-and-busulfan-induced-lung-injury-in-a-post-autologous-stem-cell-transplant-recipient
#13
Richa Jain, Kirti Gupta, Anmol Bhatia, Arun Bansal, Deepak Bansal
Veno-occlusive disease of the liver is mostly encountered as a complication of hematopoietic stem cell transplantation with myeloablative regimens with an incidence estimated to be 13.7%. It is clinically characterized by tender hepatomegaly, jaundice, weight gain and ascites. Strong clinical suspicion and an early recognition of clinical signs are essential to establish the diagnosis and institute effective regimen. Another complication of cytotoxic drugs given for cancers, is development of busulfan-induced lung injury...
September 15, 2017: Indian Pediatrics
https://www.readbyqxmd.com/read/28982297/articular-cartilage-repair-with-mesenchymal-stem-cells-after-chondrogenic-priming-a-pilot-study
#14
Troy Bornes, Adetola Adesida, Nadr Jomha
Bone marrow-derived mesenchymal stromal stem cells (BMSCs) are a promising cell source for treating articular cartilage defects. The objective of this study was to assess a protocol that involved autologous transplantation of BMSCs into full-thickness cartilage defects in sheep following isolation, expansion and a short period (4 days) of chondrogenic priming. The impact of oxygen tension during pre-implantation culture was investigated. It was hypothesized that chondrogenically primed BMSCs would produce superior cartilaginous repair tissue relative to control defects, and that culture under hypoxia would yield improved repair tissue in comparison to normoxia...
October 6, 2017: Tissue Engineering. Part A
https://www.readbyqxmd.com/read/28980775/long-term-recovery-after-endothelial-colony-forming-cells-or-human-umbilical-cord-blood-cells-administration-in-a-rat-model-of-neonatal-hypoxic-ischemic-encephalopathy
#15
Isabelle Grandvuillemin, Philippe Garrigue, Alaa Ramdani, Farid Boubred, Umberto Simeoni, Françoise Dignat-George, Florence Sabatier, Benjamin Guillet
Neonatal hypoxic-ischemic encephalopathy (NHIE) is a dramatic perinatal complication, associated with poor neurological prognosis despite neuroprotection by therapeutic hypothermia, in the absence of an available curative therapy. We evaluated and compared ready-to-use human umbilical cord blood cells (HUCBC) and bankable but allogeneic endothelial progenitors (ECFC) as cell therapy candidate for NHIE. We compared benefits of HUCBC and ECFC transplantation 48 hours after injury in male rat NHIE model, based on the Rice-Vannucci approach...
October 5, 2017: Stem Cells Translational Medicine
https://www.readbyqxmd.com/read/28980709/current-strategies-for-the-management-of-autologous-peripheral-blood-stem-cell-mobilization-failures-in-patients-with-multiple-myeloma
#16
REVIEW
Ugur Sahin, Taner Demirer
Multiple myeloma (MM) is the leading indication of autologous hematopoietic stem cell transplantation (AHSCT) worldwide. The collection of PBSCs is the essential step for AHSCT. The limits for minimum and optimum CD34(+) cells collected have been accepted as 2 × 10(6) /kg and ≥4 × 10(6) /kg for single AHSCT; 4 × 10(6) /kg and ≥8-10 × 10(6) /kg for double AHSCT. Despite the success of conventional methods for PBSC mobilization in MM, mobilization failure is still a concern depending on patient age, duration of disease, and the type of induction therapy...
October 5, 2017: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/28978848/initial-treatment-strategy-for-patients-newly-diagnosed-with-multiple-myeloma
#17
Hideo Yagi
In Japan, the latest trends in induction therapy for patients newly diagnosed with multiple myeloma are multi-drug combinations, including bortezomib, lenalidomide, and thalidomide. Patients <65 years old and those <70 years old who have normal cardiac and lung functions without any serious complications are good candidates for high-dose L-PAM with autologous stem cell transplantation. For successful stem cell collection, anti-cancer drugs that have a negative impact on stem cell mobilization are usually excluded from induction therapies...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28978845/treatment-for-mantle-cell-lymphoma
#18
Koji Izutsu
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma characterized by CD5+, CCND1+, and the CCND1-IGH translocation. Although patients with MCL respond, at least temporarily, to conventional chemotherapy, they eventually have a relapse and the prognosis is generally poor. As a primary treatment option for patients with untreated MCL, a rituximab-containing chemotherapy regimen is administered according to the patient's eligibility for high-dose chemotherapy followed by autologous stem cell transplantation (ASCT)...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28978136/nanofat-derived-stem-cells-with-platelet-rich-fibrin-improve-facial-contour-remodeling-and-skin-rejuvenation-after-autologous-structural-fat-transplantation
#19
Hua Wei, Shi-Xing Gu, Yi-Dan Liang, Zhi-Jie Liang, Hai Chen, Mao-Guang Zhu, Fang-Tian Xu, Ning He, Xiao-Juan Wei, Hong-Mian Li
Traditional autologous fat transplantation is a common surgical procedure for treating facial soft tissue depression and skin aging. However, the transplanted fat is easily absorbed, reducing the long-term efficacy of the procedure. Here, we examined the efficacy of nanofat-assisted autologous fat structural transplantation. Nanofat-derived stem cells (NFSCs) were isolated, mechanically emulsified, cultured, and characterized. Platelet-rich fibrin (PRF) enhanced proliferation and adipogenic differentiation of NFSCs in vitro...
September 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28976817/hematopoietic-stem-cell-gene-therapy-for-cerebral-adrenoleukodystrophy
#20
Florian Eichler, Christine Duncan, Patricia L Musolino, Paul J Orchard, Satiro De Oliveira, Adrian J Thrasher, Myriam Armant, Colleen Dansereau, Troy C Lund, Weston P Miller, Gerald V Raymond, Raman Sankar, Ami J Shah, Caroline Sevin, H Bobby Gaspar, Paul Gissen, Hernan Amartino, Drago Bratkovic, Nicholas J C Smith, Asif M Paker, Esther Shamir, Tara O'Meara, David Davidson, Patrick Aubourg, David A Williams
Background In X-linked adrenoleukodystrophy, mutations in ABCD1 lead to loss of function of the ALD protein. Cerebral adrenoleukodystrophy is characterized by demyelination and neurodegeneration. Disease progression, which leads to loss of neurologic function and death, can be halted only with allogeneic hematopoietic stem-cell transplantation. Methods We enrolled boys with cerebral adrenoleukodystrophy in a single-group, open-label, phase 2-3 safety and efficacy study. Patients were required to have early-stage disease and gadolinium enhancement on magnetic resonance imaging (MRI) at screening...
October 4, 2017: New England Journal of Medicine
keyword
keyword
11335
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"